Featured Articles
Novartis announces that FDA brolucizumab injection approves to be noninferior to aflibercept in Phase III studies
Novartis AG (NYSE:NVS; SIX:NOVN) has announced that the U.S. Food and Drug Administration (FDA) has approved brolucizumab (“Beovu”) injection (also known as RTH258) for the treatment of wet age-related macular degeneration (AMD). According to the company, the product is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept “and the ability […]
Read full storyPhase II study results on intravitreal (IVT) pegcetacoplan (a synthetic cyclic peptide) for the treatment of geographic atrophy (GA) secondary to ARMD
A Phase II study investigating intravitreal pegcetacoplan for the treatment of geographic atrophy (GA), secondary to age-related macular degeneration (AMD), has announced the reporting of statistically significant reductions in the growth of GA, compared with sham treatment. Results, published in the journal Ophthalmology (article in press, 2019), showed the GA growth rate was reduced by […]
Read full storyResearch on research: systematic reviews for retinal and vitreous conditions are classified as not reliable
Researchers at the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, have reported that systematic reviews for retinal and vitreous conditions were deemed to be “as not reliable”. Just under 60% of systematic reviews were judged to be inadequate and a primary concern indicates that there is a lack of a comprehensive […]
Read full story